FRESENIUS MEDICAL CARE-ADR
FMSNYSETrading Snapshot
- Day Range
- $22.43 β $22.70
- 52-Week Range
- $20.02 β $27.40
- Volume (shares)
- 803,022
- Avg Volume (shares)
- β
- Shares Outstanding
- 533.1M
- Next Earnings
- 2026-11-03
Fundamentals Snapshot
- Annual Revenue
- $19.63B
- Last Q Revenue
- $4.86B
- P/E Ratio
- 12.3
- P/S Ratio
- 0.6x
- EPS (TTM)
- $1.75
- Dividend Yield
- 3.65%
- Dilution (1yr)
- β51.3%
FRESENIUS MEDICAL CARE-ADR
FMSAbout FRESENIUS MEDICAL CARE-ADR
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates

FMS Launches multiFiltratePRO System for U.S. Patients With Acute AKI
Fresenius Medical Care launches multiFiltratePRO kidney therapy system in the United States, expanding critical care options and growth opportunities.

Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePROβ’
Expands access to Fresenius Medical Care's globally established portfolio of advanced kidney replacement therapies in the U.S. FDA clearance of multiFiltratePRO and approval of dedicated solutions expand continuous kidne

Fly Alliance to Replace Entire Flight Management System with flyExclusive's AI-Powered Contrails FMS
LAS VEGAS--(BUSINESS WIRE)--flyExclusive, Inc. (NYSE American: FLYX), one of the nation's largest private jet operators, today announced that Fly Alliance has agreed to replace its existing flight management system acros

Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026
BAD HOMBURG, Germany, Oct. 19, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, presents new research and evidence-driven innovation

Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
FMS' transformation is lifting profitability, while HDF, value-based care and cost savings offset volume and reimbursement pressures.

Fresenius Medical Care Reshapes China Portfolio for Long-Term Growth
FMS refines its China strategy around advanced dialysis and critical-care technologies, with 110M euros in one-time costs.